SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is surging as a short-seller retracted damaging allegations, sparking strong community discussion around a potential short squeeze and a significant rebound for the stock ahead of its upcoming earnings report.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending sharply lower following the FDA's Complete Response Letter for its RGX-121 gene therapy, citing concerns with trial design and a clinical hold linked to a potential tumor in a related program. The community is fiercely debating the severe impact on the company's immediate future and the broader gene therapy sector, while some highlight the continued value of other key pipeline assets.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its recent earnings report presented mixed results and conservative guidance, leading to a sharp market sell-off. Community discussion centers on whether the stock is oversold and fundamentally undervalued given its profitability, or if broader fintech sector headwinds and management's cautious outlook justify the decline.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following a mixed earnings report where strong Q4 results were overshadowed by lower-than-expected Q1 guidance, leading to a significant stock decline. The community is sharply divided, debating whether the dip presents a buying opportunity or if concerns about declining active clients and AI's impact on the gig economy are valid.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending as its stock plunged following the abrupt departures of its CFO and general counsel amid an ongoing accounting review, delayed filings, and a lowered outlook for fiscal 2026. The community is sharply divided between those calling it a "falling knife" and comparing it to past accounting scandals, and dip buyers who believe the sell-off is an "overreaction" given its revenue and stating no material impact to core financials is currently expected.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently trending as investors keenly await congressional decisions on ACA subsidies, which could significantly influence its future growth, alongside an upcoming earnings report. Sentiment among the community is polarized, with many bulls anticipating a rally on policy clarity and improved financials, while bears caution about continued losses and sector-wide pressures.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals Inc. is trending following a "blow out" earnings report that smashed estimates with strong financial performance and significant cash flow, sparking community discussions focused on the impressive beat and expectations for further guidance.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending following its Q4 earnings report and cautious Q1 revenue guidance, which, despite an EPS beat, ignited concerns about a potential "blood bath" due to an EV market slowdown and inventory. However, bullish sentiment highlights the company's strategic investments in intelligent power and sensing for AI data centers, including a new partnership with Nvidia, as key long-term growth drivers attracting dip buyers.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AgomAb Therapeutics NV is trending as a new IPO with an extremely low float, fueling intense community discussion about its potential for a short squeeze and rapid price movement, while others anticipate a pullback after its initial run.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv ($FISV) is trending as investors eagerly await its upcoming earnings report, creating a stark community divide between bulls citing undervaluation and strong fundamentals, and bears fearing another significant drop. Many are drawing parallels to recent struggles in the fintech sector and notable declines from companies like PayPal, contributing to heightened options activity and uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat.com...

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 62.3%

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 27,101...

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat reports...

vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on vTv Therapeutics in a research report on Monday. They set a "buy" rating and a $67.00 price objective for the company...

This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

Wall Street Zen upgraded vTv Therapeutics to a "sell" rating in a report on Saturday...

vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know

vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's What Happened

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50 Day Moving Average - Here's Why...

vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above 50-Day Moving Average - Here's Why

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50 Day Moving Average - Time to Sell...

Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

vTv Therapeutics Inc - Ordinary Shares - Class A

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.09	--	--	N/A
Q3 '25	-$0.98	-$1.08	-10.20%	MISSED
Q2 '25	-$0.82	-$0.92	-11.52%	MISSED
Q1 '25	-$0.81	-$0.77	5.52%	BEAT
Q4 '24	-$0.87	-$0.55	36.78%	BEAT

VTVT
vTv Therapeutics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest VTVT News

VTVTvTv Therapeutics Inc - Ordinary Shares - Class A